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Abstract
Background: Guillain‐Barré syndrome (GBS) is a rare inflammatory peripheral nerve
disorder with variable recovery. Evidence is lacking on experiences of people with
GBS and measurement of these experiences.
Objective: We aimed to develop and validate an instrument to measure experiences
of people with GBS.
Design: We used a cross‐sectional design and online self‐administered questionnaire
survey. Question domains, based on a previous systematic review and qualitative study,
covered experiences of GBS, symptom severity at each stage, healthcare and factors
supporting or hindering recovery. Descriptive, exploratory factor and reliability analyses
and multivariable regression analysis were used to investigate the relationships between
variables of interest, explore questionnaire reliability and validity and identify factors
predicting recovery.
Setting and Participants: People with a previous diagnosis of GBS were recruited
through a social media advert.
Results: A total of 291 responders, of different sexes, and marital statuses, were included,
with most diagnosed between 2015 and 2019. Factor analysis showed four scales:
symptoms, information provided, factors affecting recovery and care received. Positive social
interactions, physical activity including physiotherapy and movement, changes made at
home and immunoglobulin treatment were important for recovery. Multivariable models
showed that immunoglobulin and/or plasma exchange were significant predictors of re-
covery. Employment and recovery factors (positive interactions, work support and
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changes at work or home, physical activity and therapy), though associated with recovery,
did not reach statistical significance.
Conclusion: The questionnaire demonstrated good internal reliability of scales and
subscales and construct validity for people following GBS.
Patient Contribution: Patients were involved in developing and piloting the
questionnaire.
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1 | INTRODUCTION
Guillain‐Barré syndrome (GBS) is a rare inflammatory disorder,
affecting peripheral nerves, with an incidence of 1–2/100,000 per
year.1 The disorder produces symmetrical weakness and numbness of
the limbs, progressing proximally usually over 2–4 weeks, with
symptom onset to nadir within 6 weeks. There are several atypical
variants of GBS including Miller Fisher syndrome, which can affect
cranial nerves (causing eye, facial or swallowing problems), balance
and coordination and Bickerstaff brainstem encephalitis, which also
affects the central nervous system, and although some investigations,
such as nerve conduction studies and cerebrospinal fluid analysis are
supportive, the diagnosis is largely made clinically.2
The severity of GBS is variable, with patients with mild GBS ex-
periencing little disability and recovering spontaneously, but in 20%–30%
of cases, a more severe generalized form rapidly progresses to affect
facial and respiratory muscles, and causes symptoms leading to
more severe disability or even death.3 Treatment, particularly for more
severe cases, may involve life‐saving supportive therapy at the intensive
care unit, administration of intravenous immunoglobulins or plasma
exchange (PE), which significantly shortens the time to (but not the extent
of) recovery,4,5 followed by rehabilitation.6
Large prospective studies such as the International GBS Out-
come Study (IGOS) have shown wide variations in outcomes.7,8 Many
patients, particularly those with mild forms of GBS, recover com-
pletely within 1–2 years, but others will have residual or long‐lasting
physical, psychological or social sequelae. Physical effects include
pain, chronic fatigue and difficulty in walking.3,9 Reported psycholo-
gical symptoms include experiences of sleep disturbance, anxiety or
posttraumatic stress disorder, which can affect a person's daily life
activities, work or social function over years.10
A recent systematic review and metasynthesis of qualitative
studies of people with GBS showed the complexity of experience
of the illness, its care and rehabilitation from illness onset to
hospitalisation with acute symptoms, recovery and adjustment in
the case of longer‐term problems.11 This and other studies of
patient‐reported experiences of neurological conditions have
identified common factors associated with care quality.12
A further qualitative study exploring those factors associated
with recovery demonstrated the importance of early diagnosis,
positive experiences of inpatient care, active support for re-
covery and good communication and information provision.13
Quality in healthcare is widely considered to consist of three
interrelated components: safety, effectiveness and experience.14,15
Tools such as the Inflammatory Rasch‐built Overall Disability Scale,
the Medical Research Council sum score and the Inflammatory
Neuropathy Cause and Treatment disability score have been used to
monitor the effectiveness of treatment and disease progression.16
Healthcare experiences include ‘experiences of what health services
and staff are like and do’ and experiences of how they feel services
‘enable [them] to be and do what [they] value being and doing within
and beyond [their] healthcare encounters’.17 Patient‐reported
experience measures (PREMs) are widely used to assess patient
experience as a key aspect of quality.18,19 This is also relevant and
important for patients' experiences of conditions such as GBS and its
variants.
We aimed to develop and validate a questionnaire to quantify
experiences of people with GBS.
2 | METHODS
2.1 | Design
We used a cross‐sectional design using a self‐administered online
questionnaire survey designed to explore symptoms, care experi-
ences and recovery in people who previously had GBS.
2.2 | Questionnaire development
Questionnaire domains and items were based on a systematic review
and metasynthesis of qualitative studies11 and an interview study of
people with the condition.13 The domains for people who previously
had GBS included participant characteristics; severity of symptoms
(physical, psychological and social) at each stage of illness; medical
health‐seeking experience; treatment and care experiences; follow‐
up and support; and social or work‐related experience.
The initial questionnaire was piloted with four people who had
recovered from GBS, of whom two had taken part in an earlier
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interview study.13 The questionnaire was also discussed with the
Guillain‐Barré Syndrome and Associated Inflammatory Neuropathies
(GAIN) charity, the Healthier Ageing Patient and Public Involvement
group at the University of Lincoln and members of the research team.
Comments and suggestions were used to revise some of the ques-
tions to ensure that they were appropriate for the intended popu-
lation of GBS patients.
2.3 | Participant recruitment and data collection
Ethical approval was obtained from the University of Lincoln Human
Ethics Committee (2019‐Jul‐0738). A convenience sample of people
with GBS living in the United Kingdom was recruited through a social
media advertisement posted on Twitter and the UK GBS charity,
GAIN website, Facebook page and member list. Information about
the research (including consent and a link to the questionnaire) was
posted at the GAIN and University of Lincoln Community and Health
Research Unit websites (https://www.cahru.org.uk/) accessible to
potential participants. Participants, who self‐identified with a diag-
nosis of GBS, consented and completed the questionnaire online. No
financial incentives were given to responders. Participants were en-
couraged to contact a member of the research team (J. A.) if they
needed further information or assistance to complete the ques-
tionnaire. The survey remained open for 2 months (August and
September 2019), and once completed by participants, the ques-
tionnaire was retrieved and stored securely for analysis.
2.4 | Data analysis
The internal consistency of the GBS questionnaire was assessed
using Cronbach's α.20 This test was used to establish the level of
agreement between items belonging to the same scale. Four main
scales were developed, which contained items scored on a 7‐point
Likert scale including symptoms, care received, factors affecting
recovery and information provided. Some of these scales were divided
into further subscales: initial, in‐hospital, after‐hospital and current
symptoms as well as care received in hospital and after discharge
from hospital.
Factor analyses were run to identify questionnaire subscales.
The scales included were suitable for this type of analysis as in-
dicated by the Kaiser–Meyer–Olkin measure, which was higher
than 0.7 for all of them. Retained factors were those with ei-
genvalues greater than 1 and items with loadings higher than
0.4.21 As such, the scales included in the factor analysis (FA) were
symptoms (initial, in hospital, residual and current), factors
affecting recovery and information provided.
Multivariate linear regression models were used to identify
the factors predicting recovery. Two regression models were run:
The first one using the scales of the questionnaire as predictors
and the second one using the subscales derived from factor
analyses as the main predictors together with demographic
characteristics that might have influenced the outcome. These
demographic predictors included age and the binary variables: sex
(female or male), employment status (employed or unemployed)
and living with someone else or alone. The recovery score, which
was used as the main outcome, was computed using the formula:
recovery score =mean score of in hospital symptoms −mean score of
present symptoms.
The assumption of normality was met as indicated by both his-
tograms and P–P plots of residuals. Homoscedasticity was present as
indicated by scatterplots. The assumption of no multicollinearity was
also met for both models as indicated by Durbin Watson tests with
values close to 2 (1.93 for the first model and 2.12 for the second
model), tolerance values higher than 1 and Variance Inflation Factor
values smaller than 10.
3 | RESULTS
3.1 | Responder characteristics
In total, 291 participants responded fully or partially to the
questionnaire. Table 1 shows the demographic characteristics of
the participants who responded. Of the responders, 123 (45.6%)
were aged between 60 and 79 years; 140 (51.9%) were male and
130 (48.1.%) were female. Most participants were of White
ethnicity (264, 97.8%) compared with the minority, who were
either BAME (2, 0.7%) or mixed race (3, 1.1%) or other (1, 0.4%).
178 (65.9) were married or in civil partnership compared with 57
(21.1%) who were single or 35 (13.0%) who did not declare their
marital status. At the time of the survey, most participants (252,
86.6%) resided in the United Kingdom compared with non‐UK
residence (39, 13.4%). More participants were retired from work
(89, 38%) compared with those in full‐time employment
(55, 23.5%) or part‐time work (31, 13.2%) or those on disability
and/or other benefits and not working (30, 12.8%). At the time of
the study, the majority of participants (177, 65.6%) were living
with their spouse compared with other family members (27, 10%)
or alone (38, 14.1%) or other (27, 10%).
Disease characteristics of the responders are shown in Table 2.
Most responders had a diagnosis of GBS (202, 74.8%) compared with
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
(46, 17.0%) or a related condition (22, 8.1%). Most responders sought
help within the first 3 days (158, 60.3%) of feeling unwell and help
was most commonly sought from a general practitioner (GP) surgery
(163, 62.2%) compared with the emergency department (67, 25.6%).
Most responders (166, 64.6%) received a GBS diagnosis or its variant
rather than a different diagnosis (91, 35.4%), 106 responders re-
ceiving it on their first visit.
Overall, 116 (of 291 responders, i.e., 43%) were diagnosed between
2015 and 2019, and time to diagnosis was usually 1–7 days (161, 61.7%)
compared with later (100, 38.3%). Responders were generally treated in a
hospital general ward or an intensive care unit (76, 31.8%) and a hospital
general ward or a regional neurological unit (71, 29.7%).
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3.2 | Reliability of scales and subscales
The reliability (internal consistency) of the main scales was excellent
for symptoms (α > .9), good for information provided and for factors
affecting recovery (α > .8) and acceptable for care received (α ≥ .7).
Importantly, none of the scales had poor reliability (α ≤ .6).20 Overall,
these results presented inTable 3 indicate that the questionnaire was
a reliable measure, with good internal consistency.
Further subscales were identified following FA. Symptoms included
the following subscales: peripheral nerve symptoms, cranial nerve and
respiratory symptoms and psychological symptoms. Factors affecting
recovery included positive interactions, work support, changes at work,
changes at home, physical activity, therapy and other subscales. Because
the subscale, ‘other’, had a very low reliability, the items of this subscale
were introduced separately in the regression models. These two items
were immunoglobulin treatment and caring responsibilities. The in-
formation provided was divided into two further subscales: provided by
specialists including physiotherapists, occupational therapists and by
nonspecialists including nurses, junior doctors and GPs. A detailed ac-
count of each subscale and the items in these can be seen in Table S1.
The internal reliability of the new subscales is presented in Table 4.
The reported severity of symptoms for each subscale at different
time points (initial before admission to hospital, in hospital, residual
and current, i.e., when responders were completing the ques-
tionnaire) indicated that symptoms were most severe when re-
sponders were in hospital and those affecting the peripheral nervous
system were most prominent (Figure 1).
Responders were more satisfied with the information provided
by specialists rather than nonspecialists (Figure 2 and Table S2).
A combination of physical, psychological and social factors was
associated with recovery; these factors were identified following the
FA and an average score was calculated for each factor; details can
be seen inTable S3. The factors considered by responders to be most
important for recovery were positive social interactions, physical
activity including physiotherapy and movement, changes made at
home and immunoglobulin treatment (Figure 3).
3.3 | Prediction models
Multivariable regression models were fitted to the data. The
predictors used were gender, age, employment status and living
TABLE 1 Participants' demographic characteristics
Characteristic Number (N) Percentage (%)
Age (years)


















Civil partnership 10 3.7
Single 57 21.1
Other 34 12.6
Prefer not to say 1 0.4
Total 270 100
Residence
United Kingdom 252 86.6
Non‐United Kingdom 39 13.4
Total 291 100
Employment status
In full‐time time work 55 23.5
In part‐time work 31 13.2
In work with disability and/or other
benefits
6 2.6










Characteristic Number (N) Percentage (%)
Other family member 27 10
Alone 38 14.1
Other 27 10
Prefer not to say 1 0.4
Total 270 100
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alone or with someone, since these variables had been previously
shown to influence recovery.11,13 In the first regression model,
the main scales of the questionnaire (shown in Table 5) were in-
cluded as predictors. In the second regression model, the main
subscales of the questionnaire (shown inTable 6) were included in
the model. The results indicated that immunoglobulin and/or PE
treatment were significant predictors of recovery.
TABLE 2 Participants' disease characteristics




Related condition 22 8.1
Total 270 100









General practitioner surgery 163 62.2
Emergency department 67 25.6
Other (please state) 32 12.2
Total 262 100.0
Delay in days after first visit
1–7 days 161 61.7
8–14 days 31 11.9
15–28 days 28 10.7


















Intensive care unit (ICU) 40 16.7
(Continues)
TABLE 2 (Continued)
Characteristic Number (N) Percentage (%)
Hospital general ward 36 15.1
Received
Hospital general ward and ICU 76 31.8
Hospital general ward, outpatient 16 6.7









Abbreviations: CIDP, chronic inflammatory demyelinating
polyradiculoneuropathy; GBS, Guillain‐Barré syndrome.
TABLE 3 Reliability of each scale and subscale of the GBS
questionnaire
Cronbach's α Items Observations
Scales
Symptoms 0.94 56 60
Care received 0.70 9 175
Factors affecting recovery 0.80 28 47
Information provided 0.88 11 208
Subscales
Symptoms
Initial symptoms 0.89 13 158
Hospital symptoms 0.88 13 156
Residual symptoms 0.86 13 163
Current symptoms 0.89 13 172
Care received
In hospital 0.65 4 232
After 0.56 4 181
Abbreviation: GBS, Guillain‐Barré syndrome.
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4 | DISCUSSION
4.1 | Main findings
The high completion rate and low rates of missing data for most
questions supported the content and face validity of the ques-
tionnaire. The questionnaire showed reliability as excellent for
symptoms, good for information provided and factors affecting recovery
and acceptable for care received and symptom subscales. Physical,
psychological and social factors were associated with recovery, and
concordance with recent studies11,13 supports construct validity.
Factors considered by responders to be most important for recovery
were positive social interactions, physical activity, changes made at
home and immunoglobulin treatment. Responders were more
satisfied with information provided by specialists rather than
nonspecialists. Multivariable models showed that immunoglobulin
and/or PE treatment were significant predictors of recovery.4 Being
in employment and recovery factors in combination (positive social
interactions, support and changes at work support, changes at home,
physical activity and counselling or occupation therapy) were posi-
tively associated with recovery, but this did not reach statistical
significance.
4.2 | Comparison with the existing literature
Although many people with GBS are told that they will recover and
some do so completely, many are still affected in the longer term.
Early results from the largest ongoing prospective study, the IGOS,7
have shown that 8% could not walk and 7% had died at 1 year, with
wide international variations in outcome.8 Previous studies have also
shown long‐term neurological deficits in most patients after a year or
beyond.22,23 Furthermore, a third had changed work or were affected
in their functional ability and half had altered their leisure activities.22
Psychological24 and social dysfunction25 often persist longer term,
affecting health‐related quality of life.26
Previous research has suggested a wide variation in positive and
negative experiences at various stages of treatment and recovery
from GBS.11,13 We also found wide variations in experiences of care
from different healthcare professionals during the illness journey,
with the most positive experiences of care in hospital, from con-
sultants, followed by nurses and therapists. Consultants, followed by
physiotherapists were also rated highly for care at follow‐up, and
although in this study physical, psychological and social support were
(nonsignificantly) associated with improvement in symptoms, ex-
periences of care and psychosocial support remain important aspects
of quality of care.
Rehabilitation studies, involving careful follow‐up, show positive
benefits of rehabilitation on function27 and mortality28 before
discharge from hospital, but intensive physiotherapy beyond 6
months was also found to improve functional outcomes.6 Responders
in our study valued physiotherapy and perceived this to improve their
recovery, but shortfalls in provision for both inpatient and outpatient
rehabilitation have been found in previous studies.29,30
Positive social interactions and changes at home were also as-
sociated with recovery in this study. Positive social interactions in-
clude family or peer support.13 A systematic review found that peer
support as a potential intervention for recovery in critical care po-
pulations reduced psychologic morbidity and improved self‐efficacy,
although the quality of included studies was low.31 Finally, com-
plementary therapies such as acupuncture, vitamins and hyperbaric
oxygen have been used as an adjunct to conventional treatment, but
the only nonrandomized study was deemed of low quality.32
TABLE 4 Internal consistency of subscales identified following
factor analysis
Cronbach's α Items Observations
Subscales
Prompted symptoms




Psychological 0.78 3 180
Hospital symptoms




Psychological 0.75 3 182
Residual symptoms




Psychological 0.79 3 185
Current symptoms




Psychological 0.78 4 185
Factors affecting recovery
Positive interactions 0.84 6 213
Work support 0.85 4 191
Changes at work 0.65 5 184
Changes at home 0.66 4 202
Physical activity 0.59 3 210
Therapy 0.52 2 209
Other 0.20 3 190
Information provided
Nonprofessionals 0.72 4 219
Professionals 0.67 3 223
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4.3 | Strengths and limitations
The number of questionnaires returned was sufficient for the plan-
ned analysis, and most participants who began completed the ques-
tionnaire. The sample was not intended to be representative of GBS
patients as our main aim was to explore the reliability and validity of
the questionnaire for measuring responders' experience of GBS and
its care. As such, the sample comprised mostly participants over
40 years old, while patients with more severe sequelae were less
likely to respond. The diagnosis of GBS or a variant was based on
responder self‐identification and we were unable to confirm this from
medical records. However, we considered it unlikely that people with
conditions other than GBS would identify themselves as having GBS
and then go on to complete an extensive questionnaire of their ex-
periences. Some participant characteristics such as year of and time
since diagnosis, time to seek help, number of consultations and delay
before diagnosis, place of treatment and length of hospital stay may
have been subject to recall bias.
4.4 | Implications for practice and research
The responses to the survey confirmed recent studies suggesting that
various physical, psychological and social factors were associated
F IGURE 1 Severity of symptoms for each subscale over time
F IGURE 2 Boxplot showing satisfaction with information
provided by specialists compared with nonspecialists
F IGURE 3 Boxplot of the main factors affecting recovery
illustrating the distribution of average scores for each factor, three
representing the median
TABLE 5 Questionnaire scales predicting the recovery score
Predictors
Recovery score
B β 95% CI of B p‐Value
Gender −0.33 −.31 −0.83, 0.20 .23
Age −0.29 −.15 −0.71, 0.14 .19
Employment 0.50 .20 −0.07, 1.07 .09
Household status 0.49 .16 −0.19, 1.18 .16
Care received 0.04 .03 −0.37, 0.44 .86
Factors affecting recovery 0.36 .24 −0.03, 0.74 .07
Information provided 0.22 .20 −0.10, 0.54 .17
R2 = .32, F (7,64) = 4.24, p = .001
Abbreviation: CI, confidence interval.
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with recovery.11,13 Because the survey showed good evidence of
face and construct validity and internal consistency, it could be used
to assess patient experience and how experience of care and support
could be improved in a larger population of people with GBS.
Further research needs to be done to develop patient‐reported
outcome measures33 and PREMs for GBS beyond traditional dis-
ability measures such as the GBS Disability Scale.34 The experience
scales developed in this survey could be used to develop and eval-
uate the effect of interventions designed to improve experiences at
various stages of treatment and recovery including in the longer term,
including better access to rehabilitation and innovative social inter-
ventions such as peer or employer support.
5 | CONCLUSION
Our findings showed that the GBS patient experience survey showed
characteristics of a good measure, with evidence of internal consistency
and construct validity. The GBS patient experience questionnaire should
be tested more widely to seek further evidence of reliability, construct
validity and sensitivity to differences in care and setting.
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